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Abstract
One of the most ignored aspects of the COVID-19 pandemic has been the impact of 
public health measures by governments on wider health and welfare. From March 2020, 
hospitals in the UK saw a dramatic reduction in patients with cancer presenting due to 
multifactorial reasons. The impact of the pandemic on patients with cancer in the South 
East London Cancer Alliance was studied. The specific aims were (1) to examine the 
reduction in cancer diagnoses during the first wave of the pandemic and (2) to examine 
the stage of diagnosis of patients with cancer presenting during the pandemic compared 
with that of patients presenting before the pandemic.
There was an 18.2% reduction in new cancer diagnoses (an estimate of 987 cancers), 
when compared with 2019. This fall in cancer diagnoses was most marked in patients 
with prostate (51.4%), gynaecological (29.7%), breast (29.5%) and lung (23.4%) cancers. 
There was an overall 3.9% increase in advanced stage presentation (Stages 3 and 4), 
with an overall 6.8% increase in Stage 4 cancers during this period. The greatest shifts 
were seen in lung (increase of 6.3%, with an 11.2% increase in Stage 4 cancer alone) and 
colorectal (5.4%) cancers. For prostate cancer, there was an increase in 3.8% in those 
presenting with Stage 4 disease. For breast cancer, there was an 8% reduction in patients 
diagnosed with Stage 1 cancer with commensurate increases in the proportion of those 
with Stage 2 disease.
The experiences in cancer are a salient warning that pandemic control measures and 
policy need to balance all health and welfare. Alternative strategies need to be adopted 
during further waves of the current and any future pandemic to ensure that patients with 
cancer are prioritised for diagnosis and treatment to prevent late-stage presentation and 
an increase in avoidable deaths.
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Background
One of the most ignored aspects of the COVID-19 pandemic has been the impact of public health measures—non-pharmaceutical inter-
ventions (NPI)—by governments on wider health and welfare. NPI measures such as ‘stay at home’ orders coupled with changes in public 
behaviour due to fear of hospitals and reduction in provision of services, e.g., surgery, has radically changed health ecosystems. Patients 
with new symptoms suggestive of cancer have chosen to delay their attendance with primary healthcare or hospital practitioners due to 
concern about attending healthcare facilities and the risk of contracting SARS-COV-2 [1] or because of compliance with government orders. 
Furthermore, the suspension of cancer screening and the dramatic reduction in endoscopic and cancer surgical services resulted in fewer 
patients with a new cancer diagnosis being referred and treated [2–6]. From March 2020, hospitals in the UK saw a dramatic reduction in 
cancer patients presenting through the urgent 2-week cancer pathway and cancer screening services. The reasons were multifactorial and 
included government ‘Stay at home’ public health messaging during the peak of the pandemic and cessation of breast, colorectal and cervical 
cancer screening services. In addition, there was significant contraction of diagnostic and treatment services, particularly endoscopy as the 
pandemic began to unfold.
As a result of healthcare systems reassigning resources in preparation for the COVID-19 pandemic, cancer surgery and radiotherapy have 
been deferred and the use of systemic treatments reduced [7, 8] despite calls to prioritise cancer patients’ treatment [9]. The direct impact of 
this strategy on patients with cancer is unclear. Modelling studies suggest that as a result of COVID-19, there will be in future, a significant 
impact on late-stage presentation and the number of avoidable cancer deaths [10, 11]. It has been predicted that for four major tumour 
types—breast, colorectal, lung and oesophago-gastric cancers, diagnostic delay alone during the pandemic will result in 3,500 additional 
cancer deaths due to the pandemic and up to 60,000 life years lost. However, to date, there has been no examination of actual trends in 
hospitals.
The South East London Cancer Alliance is a major cancer hospital network which encompasses three NHS trusts (Guy’s & St Thomas’ NHS 
Trust, King’s College Hospital NHS Trust and the Lewisham and Greenwich NHS Trust) covering a large (c. 2 million), socio-demographically 
diverse population. The population served by this network is representative of other large conurbations within the United Kingdom (National 
Cancer Registration and Analysis Service). This network treats all major cancers providing diagnostic and specialist treatment services with 
just under 8,000 cancer diagnoses each year.
In this study, we consider the impact of the COVID-19-pandemic NPI on patients with cancer in this network. Specifically, we aim to (1) 
to examine the reduction in cancer diagnoses during the first wave of the COVID-19 pandemic and (2) to examine the stage of diagnosis 
of patients with cancer presenting during the pandemic compared with the stage of diagnosis of cancer patients presenting before the 
pandemic across several tumour types. We hypothesise that as a result of the reduction of patients with cancer presenting to primary or 
secondary care, there will be a significant shift in stage at diagnosis with an increase in Stages 3 and 4 presentation across multiple tumour 
types. Stage migration was assessed in four ‘bell weather’ tumour types: breast, colorectal, lung and prostate cancer. These are the four 
commonest cancer types in the UK accounting for 55.6% of all cancers. They are also characterised by differences in age profile of patients; 
screening protocols and diagnostic investigations and provide an opportunity to understand better the differential impact of the COVID-19 
pandemic on the cancer referral and diagnostic pathway.
Methods
Study population
I. All patients newly diagnosed with cancer in the South East London Cancer Alliance that were discussed at a tumour-specific multi-
disciplinary meeting between January 2019 and September 2020 were included in the study. Any diagnoses marked as recurrence or 
progression were excluded. In all, a total of 5,423 new cancers were diagnosed during this period.
II. A sub-study examined in more detail the fall and recovery trends of new diagnoses in patients with breast (International Statistical 
Classification of Diseases and Related Health Problems (ICD) C50), colorectal (ICD C17-C21), gynaecological (ICD C51-C58), head and 
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III. A further sub-study focused on patients diagnosed with breast, colorectal, prostate and lung cancer at Guy’s & St Thomas’ NHS Trust 
to assess variation in stage of presentation in two 6-month periods before and after the introduction of pandemic lockdown measures. 
Staging data were collected between October 2019 and March 2020 and compared to stage at presentation between April 2020 and 
September 2020. 
Data sources
Data were sourced from four electronic cancer data collection systems across the South East London Cancer Network. This included (1) 
MOSAIQ electronic patient record (Guy’s and St Thomas’ NHS Trust), (2) Somerset Cancer Register (Guy’s and St Thomas NHS trust), (3) 
Somerset Cancer Register (King’s College Hospital), and (4) Somerset Cancer Register (Lewisham and Greenwich). 
Staging information was missing in 10%–40% of patients through the electronic record system and therefore detailed case note review 
was used to supplement staging information to ensure close to 100% completion for the four tumour types in which stage migration was 
assessed. 
Statistical analysis
Chi squared test was undertaken to assess for any statistically significant differences in cancer stage at the time of cancer diagnosis pre and 
post first wave of the pandemic. All analyses were done using Stata version 16.
Results
Cancer diagnoses and recovery rates in South East London patients
In all, a total of 5,423 new cancers were diagnosed between 1 January and 30 September 2020. There was a significant fall in the number 
of newly diagnosed patients with cancer from March 2020 with a gradual recovery over subsequent months to expected levels by the end 
of September 2020 (Table 1; Figure 1). Overall, there was an 18.2% reduction in new cancer diagnoses (an estimate of 987 cancers), when 
compared with 2019 (mean monthly cancer diagnosis: 675 patients). This fall in the number of new cancer diagnoses was most marked in 
patients with prostate (51.4%), gynaecological (29.7%), breast (29.5%) and lung (23.4%) cancers. The fall in diagnoses and recovery trends in 
six tumour types: breast, colorectal, gynaecology, head and neck, prostate and lung is shown in Figure 2. Slow recovery rates were observed 
in breast, gynaecological, lung and prostate cancers (Figure 2).
Stage of presentation at Guy’s and St Thomas
Cancer staging of patients presenting between April 2020 and September 2020 was compared with cancer staging of patients presenting 
between October 2019 and March 2020 (Tables 2 and 3). There was an overall 3.9% increase in advanced stage presentation (Stages 3 and 
4), with an overall 6.8% increase in Stage 4 cancers during this period. The greatest shifts were seen in lung (absolute increase of 6.3%, with 
an 11.2% increase in Stage 4 cancer alone) and colorectal (5.4%) cancers (Tables 3 and 4). For prostate cancer, there was an absolute increase 
in 3.8% in those presenting with Stage 4 disease post pandemic. For breast cancer, there was an 8% reduction in patients diagnosed with 
Stage 1 cancer with commensurate increases in the proportion of those with Stage 2 disease. 
Chi Squared Test was run to determine whether there was a statistically significant difference in the proportions of patients presenting 
with Stage 1, Stage 2, Stage 3 and Stage 4 disease post pandemic compared to the pre-pandemic cohort. This demonstrated no statistically 
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Table 1. Total cancer diagnoses between January and September 2020 in South East London, broken down by individual tumour types.
TG 2020-01 2020-02 2020-03 2020-04 2020-05 2020-06 2020-07 2020-08 2020-09
Brain CNS 11 13 14 5 5 7 14 16 21
Breast 78 93 88 55 55 63 86 80 88
Colorectal 70 80 79 21 48 54 63 80 66
Gynaecology 40 45 33 34 23 23 33 31 29
Haematology 48 43 58 48 33 60 32 48 35
Head & Neck 30 33 29 23 19 27 40 32 40
HPB 30 24 21 28 31 21 23 39 45
Lung 85 74 70 46 61 71 72 73 77
Other 5 5 3 2 4 9 14 8 9
Prostate 108 131 115 28 25 36 65 53 67
Skin 100 93 95 50 80 89 98 103 130
Upper GI 39 51 33 19 30 43 26 34 44
Urology 60 48 36 27 27 41 46 38 43
Overall 704 733 674 386 441 544 612 635 694
Figure 1. Total cancer diagnoses between January and September 2020 in South East London.
Discussion
The COVID-19 pandemic has had a significant negative impact on cancer diagnoses with fewer patients presenting during the first wave (UK 
lockdown in first wave from 20 March 2020), and an increase in the proportion of patients with breast, colorectal, lung and prostate cancer 
presenting with late-stage disease, which is likely to impact on their treatment and clinical outcomes.
Our results are in keeping with the findings of other studies. The UK modelling study [11] predicted an increase in avoidable deaths from 
breast, bowel and lung cancer due to delays in diagnosis during the pandemic, as a result of later stage at presentation and even at this early 
juncture in the pandemic our results suggest that stage migration is being observed. This will ultimately translate to an increase in deaths 
from cancer that otherwise could have been avoided. An observational study that compared patients presenting between January to April 
2019 and January to April 2020 in 20 cancer institutions showed a reduction in cancer patients presenting with melanoma (52%), prostate 
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months [1]. The UK National Endoscopy Database analysed the impact of the pandemic on endoscopic services and cancer diagnosis during 
three periods, pre-COVID, transition and COVID-impacted [3]. This showed an average 82% reduction in endoscopic procedures. At its low-
est point, this was 95%. Cancer detection rates fell by an average of 58% ranging from 19% in pancreatico-biliary cancer to 72% in colorectal 
cancer [3]. It is, therefore, essential that endoscopic capacity is rapidly increased to deal with the backlog of patients who will present with 
gastrointestinal symptoms suggestive of cancer. Furthermore, it is likely that patients who have not presented so far (i.e. missing) will prob-
ably present with very late stage disease.
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Table 2. Cancer staging completeness for Guy’s and St Thomas patients (breast, colorectal, 
gynaecology, head and neck, lung and prostate).
Tumour group Period % staged
Breast
Oct 19 to Mar 20 100.0
Apr 20 to Sep 20 99.4
Colorectal
Oct 19 to Mar 20 96.6
Apr 20 to Sep 20 95.1
Lung
Oct 19 to Mar 20 99.2
Apr 20 to Sep 20 96.2
Prostate
Oct 19 to Mar 20 98.8
Apr 20 to Sep 20 93.6
Overall 97.9
Table 3. Cancer staging comparison Apr 2020 to Sep 2020 versus Oct 2019 to Mar 2020. Number of cases and percentage early 
versus late stage.
Oct 2019 to Mar 2020 April 2020 to Sept 2020
Tumour group Early stage Late stage Early stage Late stage
Breast 162 71 121 54
Colorectal 53 116 20 57
Lung 98 140 61 114
Prostate 259 139 84 48
Overall 572 466 286 273
Oct 2019 to Mar 2020 April 2020 to Sept 2020 Variance  
(Late stage)Tumour group Early stage Late stage Early stage Late stage
Breast 69.5% 30.5% 69.1% 30.9% +0.4%
Colorectal 31.4% 68.6% 26.0% 74.0% +5.4%
Lung 41.2% 58.8% 34.9% 65.1% +6.3%
Prostate 65.1% 34.9% 63.6% 36.4% +1.4%
Overall 55.1% 44.9% 51.2% 48.8% +3.9%
Similarly, the breast and colorectal cancer screening programmes in the Netherlands were suspended to decrease pressure on health services 
overwhelmed by COVID-19 allow reallocation of staff and personal protective equipment (PPE) and to reduce the spread of COVID-19 [2]. 
As a consequence of this, there were fewer diagnosis of colorectal and breast cancer particularly in the screening age groups. This has gradu-
ally increased to expected levels, but it is unknown if as a consequence of this there will be stage migration which will alter clinical treatment 
and result in worse outcomes [2].
In order to prioritise the management of patients with cancer during the COVID-19 pandemic, clinicians have created treatment algorithms 
based on the likely impact of the delays in treatment on patients’ outcomes. For example, it is reasonable to defer treatment of low-grade 
non-muscle invasive bladder cancer and to prioritise muscle-invasive bladder cancer [6]. In addition, the creation of COVID-free pathways to 
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Table 4. Cancer staging comparison Apr 2020 to Sep 2020 versus Oct 2019 to Mar 2020. Number of cases and percentage 
breakdown at Stages 1–4.
Oct 2019 to Mar 2020 Apr 2019 to Sep 2020
Tumour group Stage 1 Stage 2 Stage 3 Stage 4 Stage 1 Stage 2 Stage 3 Stage 4
Breast 93 69 46 25 55 66 31 23
Colorectal 21 32 75 41 10 10 37 20
Lung 77 21 51 89 45 16 29 85
Prostate 38 221 84 55 18 66 25 23
Overall 229 343 256 210 128 158 122 151
Oct 2019 to Mar 2020 Apr 2019 to Sep 2020 Variance 
(Stage 4)
Greatest shift  
between stagesTumour group Stage 1 Stage 2 Stage 3 Stage 4 Stage 1 Stage 2 Stage 3 Stage 4
Breast 39.9% 29.6% 19.7% 10.7% 31.4% 37.7% 17.7% 13.1% +2.4 1–2
Colorectal 12.4% 18.9% 44.4% 24.3% 13.0% 13.0% 48.1% 26.0% +1.7 2–3
Lung 32.4% 8.8% 21.4% 37.4% 25.7% 9.1% 16.6% 48.6% +11.2 3–4
Prostate 9.5% 55.5% 21.1% 13.8% 13.6% 50.0% 18.9% 17.4% +3.6 3–4
Overall 22.1% 33.0% 24.7% 20.2% 22.9% 28.3% 21.8% 27.0% +6.8 3–4
Modelling studies have been conducted to determine the potential delay in cancer diagnosis on increased mortality [10, 11], it has been 
shown that modest delays of 3–6 months in cancer surgery will result in a significant impact on survival. These studies have examined the 
reduction in cancer referrals with potential outcome and have shown an increase in avoidable deaths. This is compounded even further by 
failure to increase diagnostic capacity to clear the backlog of cancer patients as referrals increase [10, 11].
A recent paper presented at the annual San Antonio Breast Cancer Conference in December 2020 showed that 64% fewer patients were 
diagnosed with breast cancer than a year ago and more patients presented with more advanced stage and aggressive sub-types of breast 
cancer during the COVID-19 pandemic compared with the same period in 2019 [12].
The South East London population contains some of the most deprived populations in England [13]. Our analysis was not able to determine, 
at this time point, whether socioeconomic status, geography, gender and/or age were associated with a statistically significant increase in 
stage migration.
Our findings have significant implications for economics of cancer care. It is well documented that late stage disease has higher direct health-
care costs [14], but furthermore the premature mortality and morbidity will also increase, indirectly, the economic burden on countries [15].
NPIs have also had an impact on patients’ comorbidities. At Guy’s and St Thomas NHS Trust, therapy and rehabilitation services have had 
to provide urgent/essential interventions with a focus around avoidance of admission and rapid interventions for symptom management to 
enable patients to continue treatment. Capacity to provide interventions to prevent deconditioning has been limited although virtual means 
have been utilised where possible to support patients and keep them well at home to avoid hospital admission. Patients presenting currently 
have lower levels of function, higher levels of symptom burden and require substantial input from therapy services to enable them to safely 
remain at home. Since coming out of lockdown and as face-to-face activity has increased, there has been a rapid rise in referrals for patients 
requiring urgent assessment. These patients are typically highly symptomatic and require rapid intervention from the therapies and rehabili-
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Conclusion
These findings, although only from a part of the English NHS almost certainly reflect what is happening across the UK and elsewhere. In 
many countries, the impact of national lockdowns (NPI), fear of hospitals as sources of contagion and the reduction in the provision of cancer 
services are likely to have an even greater impact. Few countries have taken into account the indirect impact of public health measures on 
non-COVID-19 healthcare. The experiences in cancer are a salient warning that pandemic control measures and policy need to balance all 
health and welfare. Alternative strategies need to be adopted during further waves of the current pandemic and any future pandemics to 
ensure that patients with cancer are prioritised for diagnosis and treatment in order to prevent late-stage presentation and an increase in 
avoidable deaths. Analyses such as this should be updated regularly throughout the pandemic and beyond to understand diagnosis and stage 
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